港股创新药ETF（159567）盘初飘红，信达生物涨超4%，机构：创新药板块有望迎来业绩与估值双重修复投资机会

七印授权

14WCXO32KG13MJI2SD3VHUTU19HA1GSCPQFHKTSP3HU52LBWG2

2025-03-27 02:42:16

article

46BBD71B74957EC5CA5B4AB5D1ABD79B08063F09DDC368EF6EE494D5AB6FE4DA

zh-CN

134CC7AE547205FCE1E685FB8CBE45442C387690

18143737

02636d79fc7c7cc37b9cb348037eec28743d030e5d570d0d69837a3587bed31880

5bc927500366e84beb48360d003c5bb9514ccdd155f18d160ec92d005e97df1a75d391e9a080f6a217f418cc3044a5bf6d8f90978066f62a686c5db2257e649a1c

{"parameters":{"adaptation":"n","authorized":"七印信息科技","price":"180000"},"type":"cm"}

yuanben_67e4bb08b91b32.78410212

原本认证

5FS4FEA3J92MK84JMXH44G067CDIIP7SVMGNKZDKACBHZOHVFV

https://www.yuanben.io/article/a6ac4f1f-92bf-47e7-bfe9-1eecf535a176

{"author":"广东南方财经控股有限公司","authorization_pub_key":"03db333a8335fc94ab2e27ec5b937827ece2e576ae219f93ea1083a9a4f8882dc2"}